Novo Nordisk (NVO)
(Delayed Data from NYSE)
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Kanishka Das
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
by Zacks Equity Research
TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Novo Nordisk (NVO) concluded the recent trading session at $128.05, signifying a +1.04% move from its prior day's close.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Market Edge Highlights: LLY and NVO
by Zacks Equity Research
LLY and NVO have been highlighted in this Market Edge article.
Is Eli Lilly's Stock in a Bubble?
by Tracey Ryniec
Shares of Eli Lilly are up 150% over the last 2 years as investors are bullish about the new weight loss drugs. Is it too hot to handle?
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
by Ahan Chakraborty
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Novo Nordisk (NVO) closed at $133.28, indicating a +0.08% shift from the previous trading day.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
by Sanghamitra Saha
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
by Sundeep Ganoria
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
by Sundeep Ganoria
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
by Zacks Equity Research
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Novo Nordisk (NVO) closed at $140.87, indicating a -0.37% shift from the previous trading day.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
by Zacks Equity Research
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
PFE or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study
by Zacks Equity Research
Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
by Kinjel Shah
Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill.
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
by Zacks Equity Research
Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.